The approach improves the function of SYNGAP1-deficient neurons in vitro, but whether it will work in people remains unclear.

The drug, welcomed by patients, might be just the first of many.

The most comprehensive study of neurodevelopmental conditions in Kenya and South Africa ever conducted shares preliminary results and lessons.

Methodological choices and study-site artifacts confounded an attempt to replicate findings in support of an autism brain-imaging biomarker, according to new unpublished work.

The map diagrams more than half a million neuronal connections in the first complete connectome of Drosophila and holds clues about which brain architectures best support learning.

The new tool may pose challenges for the scientific community, but used wisely, it can help researchers save time and resources.

The two journals, although differing in initial support, both realized the need for a publication focused exclusively on the neurodiverse experience.

The proteins are part of a newly discovered complex that mends genetic damage exclusively in neurons.

After a year of intense growth, funding for biotech is in decline. The result is layoffs and program cuts — and maybe some innovation.

The finding calls into question differences between autistic and non-autistic people on a decades-old theory-of-mind test involving interacting geometric shapes.